TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06326177

Intervention type: PROCEDURE
Intervention: Shoulder Strength
Description: Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.

Intervention type: PROCEDURE
Intervention: Shoulder Strength
Description: Shoulder strength will be assessed via usage of microfet hand held dynamometer. Isometric shoulder strength will be calculated in supine lying position while participant holding their arm at side with 90 degree elbow flexion. After that participant will apply maximal contraction towards external rotation while examiner resists that motion in order to prevent any motion with dynamometer. Eccentric shoulder strength will be assessed in sitting position. Participant will hold their shoulder at 90 degrees of abduction with 90 degree external rotation. Also elbow should be in 90 degree flexed position. After that examiner will give force towards neutral rotation while holding the arm. Participant will resist this motion eccentrically until neutral rotation is reached. Velocity of the shoulder should be same throughout all motion due to creation of isokinetic environment.
Study: NCT04899791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat bread enriched with hydroxytyrosol
Description: Wheat bread enriched with hydroxytyrosol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bread
Description: Wheat bread
Study: NCT05538806

Intervention type: DEVICE
Intervention: TTFields
Description: all patients will receive routine clinical care and TTFields
Study: NCT05208203

Intervention type: OTHER
Intervention: telephone call d90
Description: telephone call on day 90 to assess the primary outcome (mRs d90)
Study: NCT05815797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDD formula
Description: SDD formula consists of 23 herbal medicines

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05664477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhytoSERM
Description: PhytoSERM is a dietary supplement containing equal amounts of genistein (16.7 mg ± 10%), daidzein (16.7 mg ± 10%) and S-equol (16.7 mg ± 10%).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product with identical shape, size and color will be produced with absence of S-equol, daidzein and genistein. Ingredients include calcium carbonate, comprecel M102, croscarmellose sodium, stearic acid, Zeofree 5162, magnesium stearate, carnauba wax, coating cellulose clear (PEG), coating white (PEG), water.
Study: NCT04949581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bioelectric therapy
Description: the patient will receive microcurrent therapy from a supine lying position. the negative electrode on the incision area and the positive electrode proximal. the intensity will be less than 20 microamperes and frequency at 20 HZ.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac rehabilitation program
Description: the patient will receive cardiac rehabilitation program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac rehabilitation program
Description: the patient will receive cardiac rehabilitation program
Study: NCT04065802

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radioablation
Description: External, non-invasive radiation delivery to scar regions of heart to treat ventricular arrhythmias
Study: NCT05967533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fermented Wheat Germ Extract
Description: Given PO
Study: NCT06519253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality (VR) music intervention
Description: The VR music intervention consists of musical performance which were already recorded. This is accessible classic music. During the intervention, the participants will be able to see the musicians (and the stage, empty auditorium, etc.) and hear the music.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music only control
Description: The control group consists of the same musical performances, with the audio only
Study: NCT05767203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samplings
Description: Blood and/or skin samples
Study: NCT05466279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remazolam
Description: Remimazolam is a new drug innovation in anesthesia. It combines the properties of two unique drugs already established in anesthesia - Midazolam and remifentanil.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol (2,6-diisopropylphenol) is a hypnotic agent that is used as an induction agent and as a maintenance anaesthetic delivered by continuous i.v. infusion or intermittent i.v. bolus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam, like diazepam, is a benzodiazepine anxiolytic drug, which is used to treat anxiety, but its t ½ is much shorter or only about 2 h compared with 43 h for diazepam
Study: NCT06051084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-Delivered Mindfulness Training (MT)
Description: The program is delivered via a smartphone-based platform, which includes a progression through 30+ daily modules of brief didactic and experience-based mindfulness training (videos and animations), app-triggered check-ins to encourage engagement, and user-initiated guided mindfulness exercises to help disrupt worry cycles in the moment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: App-Delivered Coloring
Description: An app-based coloring book with a variety of designs to choose from including mandalas, animal patterns, and florals. It is designed to help individuals relax and reduce stress and anxiety based on the benefits found in past research studies.
Study: NCT05863624

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open hernioplasty
Description: Inguinal hernia is operated using open surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP hernioplasty
Description: Inguinal hernia is operated using laparoendoscopic technique
Study: NCT05899829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camlipixant
Description: Camlipixant will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin will be administered.
Study: NCT06415487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent
Study: NCT05223257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AOT
Description: Observation of video sequences showing unimanual and bimanual goal-directed actions followed by the execution of the observed actions with upper limbs for unimanual and bimanual actions.
Study: NCT05845918

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISEM CEP
Description: Participants in PRISEM CEP will undergo assessment and goal setting during the intake process to ensure that the program meets their needs. All participants partake in lifestyle programs in individual or group-based in-person activities that address cognitive, physical, social, and functional independence, education, and well-being goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISEM Remote
Description: Participants will attend 1-hour sessions weekly for 12 weeks (12 sessions) then biweekly for 8 weeks (4 sessions) and 1 session in the last month (1 session). Sessions will be group-based and will cover the following topics: 1) Program Overview, 2) Get Active, 3)Track Activity, 4) Eating Well, 5) Track Food, 6) Get More Active, 7) Energy In, Energy Out, 8) Eating to Support Health Goals, 9) Manage Stress, 10) Eat Well Away From Home, 11) Managing Triggers, 12) How to Stay Active, 13) Take Charge of Thoughts, 14) Get Back on Track, 15) Get Support (from friends and family), and 16) Staying Motivated. Sessions will include a brief presentation of the topic, followed by an introduction to tools and strategies to practice. This is a facilitated program with participants driving the direction and acting as peer support to one another.
Study: NCT04877314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: 30 overweight male volunteers who will have 3 weeks intermittent fasting which has 16 hours fasting and 8 hours eating in a day period.
Study: NCT05946174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Set A
Description: exercise sessions and meals over approximately 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Set B
Description: exercise sessions and meals over approximately 3 weeks
Study: NCT06017583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tirellizumab was administered intravenously at 200mg/d1, 21 days per cycle, with at least 4 cycles completed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.
Study: NCT05946174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Set C
Description: meals over approximately 3 weeks
Study: NCT06017583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 825mg/m2 bid, radiotherapy day concurrent chemotherapy. Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Chemotherapy regimen after radiotherapy: XELOX regimen: oxaliplatin intravenous infusion of 130mg/m2/d1+ oral capecitabine 1000mg/m2 bid/ d1-14, 21 days per cycle, at least 2 cycles completed.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SIB-IMRT
Description: The tumor and the related mesenteric region 1cm above and below were simultaneously integrated boost to 5600cGy with the intensity-modulated radiotherapy. The other dose for clinical target volume is 5000 cGy.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: IMRT
Description: The whole dose of the clinical target volume is 5000 cGy with intensity-modulated radiotherapy.
Study: NCT06354491

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI procedures will include a 20-25 exam with periodic breath holds. The imaging series will be conducted twice to assess repeatability.

Intervention type: DEVICE
Intervention: Ultrasound (US)
Description: In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.

Intervention type: DEVICE
Intervention: Ultrasound (US)
Description: In each ultrasound exam, each participant will be scanned by two sonographers to evaluate inter-operator variability. Each exam will take approximately 60 minutes to complete. The imaging series will be conducted twice to assess repeatability.
Study: NCT05364008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: Green tea extract 1650 mg/day (45% EGCG) along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1650 mg/day along with ovarian stimulation with clomiphene citrate and timed intrauterine insemination for up to 4 cycles.
Study: NCT04966364

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hypotension prediction index guided
Description: patients receiving hypotension prediction index monitoring and let the anesthesiologist' alerted the coming intraoperatiobe hypotension

Intervention type: DEVICE
Group type: OTHER
Intervention: without hypotesion prediction index guided
Description: patients receiving usual care without hypotension prediction index monitoring but with usual arterial line care
Study: NCT04817215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801
Description: Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
Study: NCT05678192

Intervention type: DRUG
Group type: OTHER
Intervention: oral menopausal hormone therapy
Description: Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg
Study: NCT05951309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inofolic combi
Description: The patients in this group were given inofolic combi once a day for 12-16 weeks
Study: NCT05678192

Intervention type: DRUG
Group type: OTHER
Intervention: oral menopausal hormone therapy
Description: Dydrogesterone 10 mg + Estradiol 1 mg/Dydrogesterone 5 mg + Estradiol 1 mg

Intervention type: DRUG
Group type: OTHER
Intervention: transdermal menopausal hormone therapy
Description: Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg

Intervention type: DRUG
Group type: OTHER
Intervention: transdermal menopausal hormone therapy
Description: Estradiol 1,5 mg + Progesterone 200 mg/Estradiol 1,5 mg + Progesterone 100 mg
Study: NCT05951309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage 500Mg Tablet
Description: The patients in this group were given glucophage three times a day for 12-16 weeks
Study: NCT05316220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Description: Oral Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Capsule
Study: NCT04817215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801
Description: Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801
Description: Randomized to receive ORMD-0801 8 mg QD or 8 mg BID or matching placebo
Study: NCT06415487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent
Study: NCT06372821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIO752
Description: Antisense oligonucleotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NIO752
Description: Antisense oligonucleotide
Study: NCT06415487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE2016
Description: Allogeneic gamma delta T (gdT) cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE2016
Description: Allogeneic gamma delta T (gdT) cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE2016
Description: Allogeneic gamma delta T (gdT) cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint anti-PD-1 antibody
Study: NCT06372821

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT06226610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: injection every two weeks while on study
Study: NCT04858880

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
Description: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation.
Description: Radiation to the prostate bed with or without addition of radiation of lymph node irradiation (non responders). Patients with PSA response continues radiotherapy as initially planned, and are not followed according to the study protocol, only according to clinical practice.
Study: NCT05824637

Intervention type: DEVICE
Group type: OTHER
Intervention: Skin Prick Automated Test
Description: skin prick test to detection sensitisation to aeroallergens

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Skin Prick Manual Test
Description: skin prick test to detection sensitisation to aeroallergens
Study: NCT05261997

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave lithotripsy and endoscopic drainage of the main pancreatic duct
Description: In addition to drug administrated in the control group, patients in this group would be treated with ESWL and endoscopic drainage of the main pancreatic duct.

Intervention type: DRUG
Group type: OTHER
Intervention: pancreatic enzyme(Pancreatin Enteric-coated Capsules or Oryz-Aspergillus Enzyme and Pancreatin Table), antidiabetic medicine(Acarbose Tablets, Glucophage, Glimepirde Tablets)
Description: Patients will receive drugs to control pancreatic insufficiency
Study: NCT06307223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% supramolecular salicylic acid
Description: The patients received weekly application of 30% supramolecular salicylic acid for a duration of 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: supramolecular active zinc
Description: The patients received daily application of topical supramolecular active zinc anti-dandruff lotion for a duration of 8 weeks.
Study: NCT06226610

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection every two weeks while on study
Study: NCT04273360

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systematic use group
Description: Patients in this group will be subjected to initial systematic PR, which will be re-evaluated every day every day between day 0 and day 14
Study: NCT05826379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Daily Goal Setting
Description: Daily step goals displayed by the study application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Daily Goal Setting
Description: Daily step goals displayed by the study application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interim Goal Prompt
Description: Short-term step goals
Study: NCT05794568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OITcontrol app monitoring
Description: App to monitor OIT patients
Study: NCT04951414

Intervention type: DIAGNOSTIC_TEST
Intervention: ICF core set
Description: KOA rehabilitation regimen based on the complete core combination of ICF was accepted
Study: NCT06196593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof™ IQ Vivity™ Toric intraocular lens
Description: Uneventful phacoemulsification and implantation of IOL
Study: NCT05082363

Intervention type: COMBINATION_PRODUCT
Intervention: C4d evaluation in lupus nephritis in serum and renal tissue
Description: C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)

Intervention type: COMBINATION_PRODUCT
Intervention: C4d evaluation in lupus nephritis in serum and renal tissue
Description: C4d plasma levels were analyzed by a unique assay specifically detecting C4d arising from complement activation and C4 plasma levels were quantified with competitive ELISA. SLE patients in activitity with and without lupus nephritis In patient with lupus nephritis we will evaluate the C4d after developing remission in the form of reduction of proteinurea less than .5g/g measured as PCR as complete response and less than50% reduction in proteinurea in partial response according to KIDGO guide line Percutaneous renal biopsies were performed in SLE and non-SLE patients under ultrasonographic guidance. 10% formalin-fixed tissue was embedded in paraffin. Four μm-thick sections were stained with hematoxylin and eosin (H\&E), periodic acid-Schiff (PAS), periodic acid methenamine silver (PAM), masson-trichrome and polyclonal rabbit anti-human C4d antibody, Renal biopsy specimens of SLE patients were assessed using the most recent modification of the World Health Organization (WHO)